TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12221364

Group type: EXPERIMENTAL
Intervention: Surgical tracheostomy (ST)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ultrasound-guided percutaneous dilational tracheostomy (PDT)
Number of subjects: 16
Study: 10444030

Group type: EXPERIMENTAL
Intervention: tcu-PA/T in patients with DIC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prothrombin fragment 1 + 2 and urokinase antigen as predictors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups (unstable angina, hip replacement, endotoxin-treated volunteers)
Number of subjects: 0
Study: 7846537

Group type: EXPERIMENTAL
Intervention: Doxorubicin (45 mg/m2)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Epirubicin (60 mg/m2)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Epirubicin (90 mg/m2)
Number of subjects: 235
Study: 2695500

Group type: EXPERIMENTAL
Intervention: 3 Gy daily on 20 consecutive days (total dose 60 Gy, TDF factor 123)
Number of subjects: 319

Group type: COMPARATOR
Intervention: 4 Gy 3 times per week until 12 irradiations (total dose 48 Gy, TDF factor 103)
Number of subjects: 319
Study: 353832

Group type: EXPERIMENTAL
Intervention: Flunarizine (Sibelium)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30702355

Group type: EXPERIMENTAL
Intervention: Highly trained in FCU with universal, routine monitoring
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Minimally trained in FCU with optional, variable monitoring
Number of subjects: 75

Group type: COMPARATOR
Intervention: Services as usual with no training in the FCU
Number of subjects: 75
Study: 28727591

Group type: EXPERIMENTAL
Intervention: EMLA (daily use for 4 weeks as a primary dressing)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard wound care (control group)
Number of subjects: 60
Study: 25730338

Group type: EXPERIMENTAL
Intervention: Pupillary dilatation reflex amplitude (PDRA) evoked by standardized noxious test (SNT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Estimated remifentanil effect-site concentration (Ce)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Area under the receiver operating characteristics curve for PDRA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Area under the receiver operating characteristics curve for remifentanil Ce
Number of subjects: 80
Study: 24411764

Group type: EXPERIMENTAL
Intervention: Attend healthy group
Number of subjects: 146

Group type: COMPARATOR
Intervention: Attend unhealthy group
Number of subjects: 146
Study: 22980702

Group type: EXPERIMENTAL
Intervention: Ultrasound scalpel
Number of subjects: 198

Group type: COMPARATOR
Intervention: Traditional technique
Number of subjects: 198
Study: 19356914

Group type: EXPERIMENTAL
Intervention: 10.5% energy linoleic acid (LA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3.8% energy linoleic acid (LA)
Number of subjects: 100
Study: 17641561

Group type: EXPERIMENTAL
Intervention: Acupuncture for generalised anxiety disorder or anxiety neurosis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture for perioperative anxiety
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 12

Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 12
Study: 15167083

Group type: EXPERIMENTAL
Intervention: Coping Course (n = 46)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care (n = 30)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group from a second correctional facility (n = 62)
Number of subjects: 76
Study: 11778111

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% combined with sufentanil 30 mcg (group S)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ropivacaine 0.5% combined with morphine 2 mg (group M)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% plus sufentanil 0.5 mcg/ml (group S)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ropivacaine 0.2% plus morphine 0.02 mg/ml (group M)
Number of subjects: 60
Study: 9596230

Group type: EXPERIMENTAL
Intervention: Frequent aspirin use
Number of subjects: 5011

Group type: EXPERIMENTAL
Intervention: Infrequent aspirin use
Number of subjects: 5011

Group type: EXPERIMENTAL
Intervention: Aspirin use (frequent and infrequent)
Number of subjects: 5011

Group type: COMPARATOR
Intervention: Nonusers of aspirin
Number of subjects: 5011
Study: 8115208

Group type: EXPERIMENTAL
Intervention: Enzyme immunoassay (asymptomatic)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: DNA probe (symptomatic)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Culture
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Nonculture techniques
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Overall diagnostic tests
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Overall prevalence of chlamydia
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Overall infected subjects
Number of subjects: 479
Study: 2576364

Group type: EXPERIMENTAL
Intervention: Picumast dihydrochloride (2 mg o.d.)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg o.d.)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 1278006

Group type: EXPERIMENTAL
Intervention: Forced water diuresis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Furosemide diuresis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Thirst-regulated diuresis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Forced water diuresis (oral or parenteral fluid)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Furosemide in high dosage
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Furosemide treatment
Number of subjects: 12
Study: 31166412

Group type: EXPERIMENTAL
Intervention: 3D pre‐existing planes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3D planes created from landmarks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lines created from landmarks
Number of subjects: 20
Study: 27178321

Group type: EXPERIMENTAL
Intervention: Culturally tailored physical activity program for clergy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 44
Study: 25770671

Group type: EXPERIMENTAL
Intervention: Thinking Well (TW) intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 31
Study: 23597577

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 7 days prior to PCI
Number of subjects: 202

Group type: COMPARATOR
Intervention: Immediate PCI (Control group)
Number of subjects: 202
Study: 22090167

Group type: EXPERIMENTAL
Intervention: Colchicine 1.0 mg twice daily starting on postoperative day 3 followed by a maintenance dose of 0.5 mg twice daily for 1 month (doses halved for patients <70 kg or intolerant)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 19302423

Group type: EXPERIMENTAL
Intervention: Interval exercise training (60%-79% heart rate max reserve) for 8 weeks, 45 to 60 min/day
Number of subjects: 22
Study: 17663609

Group type: EXPERIMENTAL
Intervention: Network Support (NS)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Network Support + Contingency Management (NS + CM)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Case Management (CaseM)
Number of subjects: 210
Study: 14749346

Group type: EXPERIMENTAL
Intervention: Norepinephrine (NOR) 0.16 microg/kg per min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study: 11687766

Group type: EXPERIMENTAL
Intervention: Nasal breathing with external nasal dilator strip (NBENDS)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nasal breathing with fake nasal strip (NBFNS)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Oronasal breathing (CON)
Number of subjects: 9
Study: 9935260

Group type: EXPERIMENTAL
Intervention: Trovafloxacin (intravenous alatrofloxacin followed by oral trovafloxacin for a maximum of 14 days)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Cefoxitin followed by amoxicillin/clavulanic acid (control group)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Trovafloxacin
Number of subjects: 226
Study: 15374296

Group type: EXPERIMENTAL
Intervention: CDP-choline 1000 mg/day i.m.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 2907743

Group type: EXPERIMENTAL
Intervention: Metoprolol (low-dose beta-blockade starting with 6.25 mg twice daily, increasing to a maximum of 100 mg as tolerated)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (relative placebo group receiving standard therapy including digitalis, diuretics, vasodilators, and anticoagulants as needed)
Number of subjects: 20
Study: 31864348

Group type: EXPERIMENTAL
Intervention: SHEMA intervention
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care (traditional stroke health-education)
Number of subjects: 76
Study: 29780829

Group type: EXPERIMENTAL
Intervention: Device A
Number of subjects: 34

Group type: COMPARATOR
Intervention: Device B
Number of subjects: 34
Study: 26370724

Group type: EXPERIMENTAL
Intervention: 2 mL of 2% lidocaine with epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 mL saline
Number of subjects: 60
Study: 25160518

Group type: EXPERIMENTAL
Intervention: Once-daily tacrolimus extended release (Tac-ER)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Twice-daily tacrolimus immediate release (Tac-IR)
Number of subjects: 19
Study: 22268509

Group type: EXPERIMENTAL
Intervention: Single-plane treatment with 4.0 MHz, 4.5-mm depth transducer
Number of subjects: 18

Group type: COMPARATOR
Intervention: Dual-plane treatment with 4.0 MHz, 4.5-mm depth followed by 7.0 MHz, 3.0-mm depth transducer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both single-plane and dual-plane treatments
Number of subjects: 18
Study: 19281927

Group type: EXPERIMENTAL
Intervention: rHDL (80 mg/kg of apolipoprotein A-I)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 13
Study: 17940319

Group type: EXPERIMENTAL
Intervention: Insect repellent and insecticide treated bed nets
Number of subjects: 4008

Group type: COMPARATOR
Intervention: Insecticide treated bed nets alone
Number of subjects: 4008

Group type: EXPERIMENTAL
Intervention: Insect repellent
Number of subjects: 4008
Study: 15123220

Group type: EXPERIMENTAL
Intervention: formoterol/budesonide 2 x (4.5/160) microg
Number of subjects: 20

Group type: COMPARATOR
Intervention: formoterol 2 x 4.5 microg
Number of subjects: 20
Study: 12237626

Group type: EXPERIMENTAL
Intervention: Fluoxetine with oral contraceptives
Number of subjects: 1698

Group type: COMPARATOR
Intervention: Fluoxetine without oral contraceptives
Number of subjects: 1698
Study: 9842788

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50-300 mg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 7989026

Group type: EXPERIMENTAL
Intervention: HMO members receiving antipsychotic drugs or lithium
Number of subjects: 0
Study: 2564715

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 0
Study: 31250099

Group type: EXPERIMENTAL
Intervention: Probiotic mixture (2 × 1010 CFU/day of Lactobacillus acidophilus LA‐14, Lactobacillus casei LC‐11, Lactococcus lactis LL‐23, Bifidobacterium bifidum BB‐06, and Bifidobacterium lactis BL‐4)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 32
Study: 30987658

Group type: EXPERIMENTAL
Intervention: Songling Xuemaikang capsules (SXC)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study: 28834608

Group type: EXPERIMENTAL
Intervention: Self-reported smoking abstinence
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Factors associated with verification at 10 ng/ml
Number of subjects: 822

Group type: COMPARATOR
Intervention: Verification rates
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Overall verification failure
Number of subjects: 822
Study: 26332857

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 0.5 μg·kg IV bolus
Number of subjects: 400
Study: 23320520

Group type: EXPERIMENTAL
Intervention: AZD1386 (95 mg single dose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 21502898

Group type: EXPERIMENTAL
Intervention: 1:4 contrast water immersion (1 min of cold to 4 min of hot)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1:1 contrast water immersion (2.5 min of cold to 2.5 min of hot)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Passive rest
Number of subjects: 16
Study: 19185254

Group type: EXPERIMENTAL
Intervention: Tecnis Z9003 IOL
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: AcrySof SN60WF IOL
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Akreos Adapt AO IOL
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: All 3 aspheric IOLs
Number of subjects: 130
Study: 17535945

Group type: EXPERIMENTAL
Intervention: Telepsychiatry
Number of subjects: 495

Group type: COMPARATOR
Intervention: Face-to-face psychiatry
Number of subjects: 495
Study: 15146408

Group type: EXPERIMENTAL
Intervention: COBRA therapy (including temporary high-dose prednisolone, temporary low-dose methotrexate, and sulfasalazine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SSZ monotherapy
Number of subjects: 0
Study: 11535840

Group type: EXPERIMENTAL
Intervention: 0.2 percent nitroglycerin ointment (n = 19)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 39
Study: 9032100

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 30
Study: 8294171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.3 mg.kg-1
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Butorphanol 40 micrograms.kg-1
Number of subjects: 17
Study: 3565666

Group type: EXPERIMENTAL
Intervention: Diabetes education and peer support
Number of subjects: 79

Group type: COMPARATOR
Intervention: Diabetes education only
Number of subjects: 79

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 79
Study: 31844937

Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29669688

Group type: EXPERIMENTAL
Intervention: Thoracic spine thrust manipulation (TSM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mobilization
Number of subjects: 48
Study: 26709060

Group type: EXPERIMENTAL
Intervention: Ezetimibe and low-dose simvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25426862

Group type: EXPERIMENTAL
Intervention: 6-minute walk distance
Number of subjects: 2043

Group type: COMPARATOR
Intervention: LVEF
Number of subjects: 2043

Group type: COMPARATOR
Intervention: NYHA functional class
Number of subjects: 2043

Group type: EXPERIMENTAL
Intervention: MMSE <24
Number of subjects: 2043
Study: 23597333

Group type: EXPERIMENTAL
Intervention: Expectancy group (placebo cream applied)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no placebo cream applied)
Number of subjects: 58
Study: 20578644

Group type: EXPERIMENTAL
Intervention: Conventional acupuncture (13 patients)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham acupuncture (16 patients)
Number of subjects: 31
Study: 18394150

Group type: EXPERIMENTAL
Intervention: Specific training in diagnostic coding
Number of subjects: 84

Group type: COMPARATOR
Intervention: General educational program
Number of subjects: 84
Study: 16672069

Group type: EXPERIMENTAL
Intervention: PSQ-An Satisfaction subscale
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: PSQ-An Treatment burden subscale
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: PSQ-An Overall satisfaction subscale
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Test-retest reliability
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Construct validity
Number of subjects: 312
Study: 14670699

Group type: EXPERIMENTAL
Intervention: Paired-comparison method for judging relative complexity of band patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symmetry properties of band patterns
Number of subjects: 0
Study: 11008329

Group type: EXPERIMENTAL
Intervention: Captopril (25-75 mg/day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Fosinopril (5-20 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No ACE-inhibitor therapy (Control group)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Captopril or Fosinopril
Number of subjects: 52
Study: 9103725

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (16 weekly sessions)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo treatment (6-12 weeks)
Number of subjects: 76
Study: 8095251

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg (once a day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Captopril 20 mg (twice a day)
Number of subjects: 40
Study: 3527720

Group type: EXPERIMENTAL
Intervention: Bay m 1099 (100 mg before breakfast and dinner)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29763657

Group type: EXPERIMENTAL
Intervention: mHealth-based care model (daily BP measurement using smartphone and wireless BP monitor, bi-weekly medication adjustments)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (digital BP monitor provided)
Number of subjects: 50
Study: 26849087

Group type: EXPERIMENTAL
Intervention: 90% trichloroacetic acid (TCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 88% phenol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both TCA and phenol
Number of subjects: 0
Study: 25277997

Group type: EXPERIMENTAL
Intervention: LCZ696
Number of subjects: 298

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 298
Study: 22801130

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine 1:100,000
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 4% articaine with epinephrine 1:100,000
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Pressure rate quotient
Number of subjects: 47
Study: 20070849

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) intervention for panic symptoms
Number of subjects: 217

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 217
Study: 18564802

Group type: EXPERIMENTAL
Intervention: SLIPA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Classic LMA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 100
Study: 16372827

Group type: EXPERIMENTAL
Intervention: Onercept 5mg and 50mg (single intravenous doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Onercept 15mg and 150mg (single intravenous doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Onercept 50mg (single intravenous, subcutaneous and intramuscular doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Onercept 50mg (repeat subcutaneous administration of six doses every 48 hours)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Onercept 100mg and 150mg (repeat subcutaneous administration of six doses over 2 weeks)
Number of subjects: 48
Study: 11235499

Group type: EXPERIMENTAL
Intervention: New nonprescription medication
Number of subjects: 19

Group type: COMPARATOR
Intervention: Petrolatum (control)
Number of subjects: 19
Study: 9703836

Group type: EXPERIMENTAL
Intervention: 5-FU 250 mg/day with Limethason 1 A (4.0 mg of dexamethasone palmitate) in Group B
Number of subjects: 24

Group type: COMPARATOR
Intervention: 5-FU 250 mg/day in Group A
Number of subjects: 24
Study: 7816530

Group type: EXPERIMENTAL
Intervention: Diuretics treatment in infants with congenital heart disease
Number of subjects: 7

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 7
Study: 3050936

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg single dose
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg b.d. chronic dosing
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg b.d. chronic dosing
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ketanserin mean dose 73 mg/day for 7 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ketanserin mean dose 167 mg/day
Number of subjects: 41
Study: 1540479

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Simple placebo
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo with implied therapeutic action
Number of subjects: 50
Study: 351982

Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 748

Group type: COMPARATOR
Intervention: Selective gastric vagotomy (SGV) + drainage (D)
Number of subjects: 748

Group type: COMPARATOR
Intervention: Selective gastric vagotomy (SGV) + antrectomy (A)
Number of subjects: 748

Group type: COMPARATOR
Intervention: PCV + drainage (D)
Number of subjects: 748
Study: 29912724

Group type: EXPERIMENTAL
Intervention: LPs performed by right-handed physicians with patients in the left lateral recumbent position (LRP)
Number of subjects: 7200

Group type: EXPERIMENTAL
Intervention: LPs performed by left-handed physicians with patients in the right lateral recumbent position (RRP)
Number of subjects: 7200

Group type: COMPARATOR
Intervention: LPs performed by left-handed physicians with patients in the left lateral recumbent position (LRP)
Number of subjects: 7200

Group type: COMPARATOR
Intervention: LPs performed by right-handed physicians with patients in the right lateral recumbent position (RRP)
Number of subjects: 7200
Study: 28745027

Group type: COMPARATOR
Intervention: β-TCP alone (Control group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: P-PRP-mixed β-TCP (P-PRP group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PRF-mixed β-TCP (PRF group)
Number of subjects: 26
Study: 25879460

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg OaD
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg PRN
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study: 23688060

Group type: EXPERIMENTAL
Intervention: Quitted >5 years
Number of subjects: 3670

Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 3670
Study: 21297656

Group type: EXPERIMENTAL
Intervention: Modified apical dissection technique (group 2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard apical dissection technique (group 1)
Number of subjects: 42
Study: 19223620

Group type: EXPERIMENTAL
Intervention: IPTi-SP (sulfadoxine-pyrimethamine) administered at 3, 9, and 15 months of age
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: IPTi-SP (sulfadoxine-pyrimethamine)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200